The Board of Directors based on the recommendation of the Audit Committee, has approved the appointment of M/s. SARK & Associates LLP (earstwhile SARK & Associates), Practicing Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Coral Laboratories' board approved audited standalone financial results for Q4 and FY ended March 31, 2025, with statutory auditor M.A. Parekh & Associates issuing an unmodified opinion. For FY25, revenue from operations rose to ₹11,500.53 lakhs (up ~37% from ₹8,366.04 lakhs in FY24), and net profit jumped to ₹2,415.56 lakhs (up ~53% from ₹1,578.90 lakhs), translating to EPS of ₹67.61 vs ₹44.61. However, Q4 FY25 saw a sharp sequential and year-on-year profit decline to ₹282.71 lakhs (vs ₹578.70 lakhs in Q4 FY24). The board recommended a 15% final dividend (₹1.50 per share) subject to shareholder approval. It also appointed SARK & Associates LLP as secretarial auditor for 5 years (FY26–FY30), S K Doshi & Associates as internal auditor, and Aatish Dhatrak & Associates as cost auditor for FY26.
Strong full-year earnings growth and a modest dividend are positive for shareholders, but the sharp Q4 profit drop despite higher full-year numbers may draw investor scrutiny. Routine auditor appointments signal no governance concerns.